Prostate Cancer / 2014 / Article / Tab 2

Clinical Study

Cryotherapy for Primary Treatment of Prostate Cancer: Intermediate Term Results of a Prospective Study from a Single Institution

Table 2

Characteristics and Risk stratification.

Tumor characteristics

Ng/mL PSAMedian 8.25 (1,818–56,171)Mean 10.517 95% CI (9,013–12,021)
Prostate volume (cc) at diagnosisMedian 33 (range 11–91)Mean 37.13 95% CI (34,13–40,13)
Gleason
 5 ( )1 (0.9%)
 6 ( )54 (50%)
 7 ( )19 (17.6%)
 7 ( )18 (16.7%)
 8 ( )14 (13%)
 9 ( )2 (1.9%)
Stage (adapted according to
TNM 2009 classification)
 cT1c57 (52.8%)
 cT2a20 (18.5%)
 cT2b16 (14.8%)
 cT2c13 (12%)
 cT3a2 (1.9%)
Pathological report
 Right side33 (30.6%)
 Left side31 (28.7%)
 Bilateral44 (40.7%)
RISK (according to D’Amico criteria)
 Low28 (25.9%)
 Intermediate34 (31.5%)
 High46 (42.6)
Hormone treatment44 (40.7%)
Prostate volume at treatment (cc)Median 31 (range 14–80)Mean 32,66 95% CI (30.15–35,17)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.